Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORIA: Rimonabant for Visceral Fat in Metabolic Syndrome
NCT00299325Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in metabolic syndrome and Abdominal adiposity (ABCD) comparing Rimonabant with Placebo (2 arms). Primary endpoint: Relative change in visceral fat area assessed by CT scan at 12 months. Started Feb 2006; status: completed.
02
Drugs
rimonabant
03
Conditions
metabolic syndromeAbdominal adiposity (ABCD)
Beyond the preview
Go deeper on NCT00299325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299325.